Holdings

Octagon Capital Advisors LP

As of Sep 30, 2026, Octagon Capital Advisors LP reported 24 positions worth US$732M. Largest: Dianthus Therapeutics, Inc., Abivax SA and Definium Therapeutics, Inc. What it bought and sold, with each filing.

Holdings

Positions
24
Value as reported
US$732M
Holdings as of
Sep 30, 2026
Last filed
Nov 16, 2026
CompanySharesValue as reported% of company% of portfolioChangeAs of
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
1.69MUS$149M19.8%−155KSep 30, 2026
Abivax SA
EURONEXT:ABVX
993KUS$98.3M13.1%no changeSep 30, 2026
Definium Therapeutics, Inc.
NASDAQ:DFTX
2.51MUS$95.6M1.8%12.7%−439KSep 30, 2026
Cogent Biosciences, Inc.
NASDAQ:COGT
2.35MUS$75.2M10.0%no changeSep 30, 2026
ArriVent BioPharma, Inc.
NASDAQ:AVBP
2.14MUS$64.8M4.1%8.6%+170KSep 30, 2026
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
9.69MUS$47.2M3.0%6.3%no changeSep 30, 2026
Obsidian Therapeutics, Inc.
NASDAQ:OBX
2.41MUS$33.2M3.9%4.4%newSep 30, 2026
Kymera Therapeutics, Inc.
NASDAQ:KYMR
205KUS$22.9M3.1%−105KSep 30, 2026
Disc Medicine, Inc.
NASDAQ:IRON
270KUS$17.7M0.59%2.4%no changeSep 30, 2026
Tango Therapeutics, Inc.
NASDAQ:TNGX
630KUS$15.7M2.1%newSep 30, 2026
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
420KUS$15.6M2.1%−70,000Sep 30, 2026
Adlai Nortye Group Ltd.
NASDAQ:ANL
935KUS$15M1.6%2.0%newSep 30, 2026
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
169KUS$14.5M1.9%−169KSep 30, 2026
Aktis Oncology, Inc.
NASDAQ:AKTS
713KUS$13.9M1.3%1.8%−248KSep 30, 2026
Palisade Bio, Inc.
NASDAQ:PALI
10.3MUS$13.9M5.7%1.8%no changeSep 30, 2026
BioAge Labs, Inc.
NASDAQ:BIOA
1.3MUS$9.22M2.8%1.2%−448KSep 30, 2026
Gyre Therapeutics, Inc.
NASDAQ:GYRE
954KUS$7M0.83%0.93%no changeSep 30, 2026
DBV Technologies SA
EURONEXT:DBV
574KUS$6.75M0.90%no changeSep 30, 2026
Ocular Therapeutix, Inc.
NASDAQ:OCUL
600KUS$4.6M0.27%0.61%−1.48MSep 30, 2026
Trevi Therapeutics, Inc.
NASDAQ:TRVI
315KUS$4.51M0.60%no changeSep 30, 2026
Sensei Biotherapeutics, Inc.
NASDAQ:SNSE
100KUS$2.97M0.39%0.40%−261KSep 30, 2026
Precision BioSciences, Inc.
NASDAQ:DTIL
430KUS$2.69M1.5%0.36%−920KSep 30, 2026
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
275KUS$1.29M0.94%0.17%−725KSep 30, 2026
Gossamer Bio, Inc.
NASDAQ:GOSS
96,875US$1.15M1.6%0.15%−7.65MSep 30, 2026